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Abstract
Nutritional research in sickle cell disease has been the focus in recent times owing to not only specific nutritional
deficiencies, but also the improvements associated with less painful episodes. Though hydroxyurea remains the
drug of choice, certain adverse health effects on long term supplementation makes room for researches of different
compounds. Macro and micro nutrient deficiencies, along with vitamins, play an important role in not only meeting
the calorific needs, but also reducing clinical complications and growth abnormalities. Symptoms of hyper protein
metabolism, increased cell turnover, increased cardiac output, and appetite suppression due to enhanced cytokine
production, might give us leads for better understanding of the mechanisms involved. Different nutritional approaches
comprising of traditional herbal therapies, antioxidants, flavonoids, vitamins, minerals etc., reducing oxidative stress and
blood aggregation, have been tried out to increase the health potential. Nutritional therapies may also serve
complementary to the newer therapies using ozone, hematopoietic stem cell transplantation, antifungal medications,
erythropoietin etc. Herein we try to present a holistic picture of the different patho-physiological mechanisms, and
nutritional strategies adopted.
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Background
Sickle cell disease (SCD) one of the commonest preva-
lent autosomal recessive disease around the globe [1], is
an inherited hematological disorder wherein, the
oxygen-carrying molecule namely hemoglobin (Hb)
present in the red blood cell, is defective. A mutation in
the in the 6th codon of the 11th chromosome of the β
globin chain, renders the amino acid valine to be
substituted by glutamic acid resulting in HbS, the sickle
cell haemoglobin [2].
The deoxygenated HbS undergoes hydrophobic inter-
actions to form rod-like structures which are clusters of
hemoglobin protein stuck to each other. These long fi-
bers push the cell membrane out of shape causing the
whole cell to become rigid,take a sickle shape, become
deformed and adhere to the endothelium of blood ves-
sels producing vasospasms,vasoconstriction, and trigger-
ing inflammation [3, 4] Adhesion is also significantly
affected by alterations in hydration of erythrocytes. This
changes their cellular tone and the cells become sickle
shaped [5]. These red blood cells (RBC’s), due to their
increased viscosity, sludge in the circulatory system
obstructing microvasculature [6], producing oxygen defi-
ciency at the target tissue/ organ. This causes tissue
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damage leading to ischemia and infarction and a com-
promised reduced life span [7].
In most of the cases, it requires immediate
hospitalization and medical intervention with anti-
inflammatory drugs, non-steroidal analgesics, hydroxy-
urea (HU), opioid analgesics, rehydration and in severe
cases transfusion [8] which may cause other long term
side effects.
Though born with a normal weight, children affected
by SCD show weight deficits by year one which con-
tinues until adulthood accompanied by delayed skeletal
maturation in both sexes and a delayed menarche in
girls [9].
Fetal hemoglobin (HbF) is found in patients with SCD
at different levels and is known to reduce the severity of
symptoms of the disease. Hydroxyurea therapy has
gained momentum as it raises levels of HbF accompan-
ied by decreased morbidity. Though hydroxyurea is a
potent HbF inducer in adults and children, it does not
possess the ideal combination of efficacy, safety and ease
of use [10]). This calls for further researches for com-
pounds to alleviate the pain and improve the condition
of patients with SCD. Several approaches have been
made to prevent this disease or reverse the sickling
phenomenon either through technological applications
or the usage of compounds which affect the Hb mol-
ecule directly which are enlisted in the given Table 1.
Supplementation of oral antibiotics for a definite
period in childhood to prevent pneumococcal infections
is generally practiced in SCD patients. Also it has been
observed by the Cochrane Reviewers that prophylactic
penicillin considerably reduces the risk of pneumococcal
infections and it is related with negligible side effects in
SCD homozygous children, [11, 12]. The broad-
spectrum antifungal drug Clotrimazole appears to be a
well-tolerated drug, with few adverse reactions due to
drug resistance in SCD patients, who are immune-
compromised. Its metallic complexes have been also
shown to exhibit improved efficacy [13]. Pharmaco-
logical agents targeting signaling molecules are also be-
ing tried out [10]
Though morphine is the opioid of choice, [14] it has
been linked to pediatric acute chest syndrome (ACS) in
patients hospitalized with severe pain [15], when admin-
istered intravenously. The risks of newer therapies using
blood and bone marrow stem cell transplant though
curative, outweigh the benefits, thereby limiting its usage
because they are expensive and unaffordable to the vast
majority of affected patients [16].
Multiple nutrient deficiencies have been observed with
increased severity of the disease. Prevention of complica-
tions is expected from ongoing research in the nutri-
tional scenario. Nutritional intervention with potential
key nutrients has been in focus in recent times owing to
specific nutritional deficiencies [17] and improvements
in SCD associated painful episodes. Nutritional interven-
tions to correct the existing cell membrane structure,
composition and function could provide additional bene-
fit to the new preventing and curative aspects of SCD.
For example fish oils containing eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) have been
found to prevent the blockage of blood flow which could
help in alleviating the problems associated with SCD
[18]. Reduction of the vaso-occlusive crisis using zinc
and piracetam are also quite encouraging, but larger co-
horts, and/or longer term multi centric trials over a
period of time are required to evaluate their efficacy
[19]. A prospective nutritional approach with potentially
active molecules like antioxidants might also be of
benefit [20].
Interventions that are evidence based, sustainable, af-
fordable and well incorporated into the healthcare struc-
ture should therefore be looked into. This review
discusses the pros and cons of this much sought after
issue in today’s context.
Nutrient insufficiencies/deficiencies
Nutritional intake has been found to be quite poor in
SCD patients, and a serious need to correct the situation
is implied [17]. Multiple nutrient insufficiencies or defi-
ciencies of some micronutrients, vitamins, antioxidants
and certain lipid constituents have been shown to be
prevalent in patients with SCD and associated with in-
creased disease severity of the disease (Fig. 1). Many
complications associated with the disease, such as
growth retardation, delayed sexual maturity, and a weak
immune system, could be considered partly due to nutri-
tional deficiencies [21]. In an important study Mandese
et al. observed a significant relationship between body
weight, body mass index (BMI) and either concentration
of Hb or severity of the disease. They found that many
of the nutritional components (macro and micro nutrients)
are inadequate and affect the days of hospitalization for
SCD patients. Also the concentration of HbF was negatively
correlated with some of the nutrients like lipids, vitamins
and minerals. They observed maximum nutrient deficiency
in intake of Ca, Fe, vitamin B1 and C, while carbohydrates,
lipids & vitamin B2 were moderately insufficient [22]. A
study by Martyres et al. stressed out for the need of larger
sample size to establish the relationship between nutrient
deficiency and the severity of SCD [23].
Researchers have found that markers of elevated oxi-
dative stress and inflammation are expressed in adoles-
cents with SCD even in a steady state, which correlated
with their resting energy expenditure (REE) [24]. Experi-
mental studies show an imbalance in the chronic state of
oxidant and antioxidant factors in red cells of SCD
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patients, resulting in an increase of oxidative stress and
hemolysis [25].
Role of macronutrient deficiencies
An increased plasma level of some acute inflammatory cy-
tokines is observed in mice with sickle cell anemia (SCA) in
response to infection. Supplementation of high protein diet
resulted in decreased infection which can provide a clue to
decreasing the incidents of infection in children with SCA.
An increase in TNF -α, TNF- γ, IL-10, and IL-4 cytokines
has been noted in the murine model of human SCA which
is alleviated by supplementing a high protein diet [26]. In
another study, decreased levels of CRP and IL-6 are ob-
served on feeding a high protein diet [27].
Arginine plays an important role in SCD pathogenesis
as insufficient / low global arginine bioavailability (GAB)
is linked with many complications of the disease. Several
mechanisms are proposed for arginine dysregulation in
SCD patients. By inhibiting Gardo’s Channel activity ar-
ginine decreases the RBC density in transgenic SCD
mice [28].
There is increased activity of arginase, increase in
asymmetric dimethyl arginine, alteration in arginine
transport mechanism and discrepancy in NO synthesis
Table 1 Drug candidates exhibiting benefits in sickle cell disease
Drug name Action mechanism Reference
Butyrate HDAC inhibition, mood stabilization [110, 111]
Decitabine DNA demethylation [112]
Trichostatin A Increases HbF level; decrease adhesion of cells to vessel wall [113]
Pomalidomide Gammaglobin activation by Histone deacetylase [114]
Senicapoc Improves RBC hydration [115]
Nitric Oxide Increase NO [116]
Tinzaparin Decreases P-selectin-mediated acute pain episodes [117]
6R-BH4 Increases NO; improve endothelial function [118, 119]
Sidenafil Increases NO [116]
Eptifibatide Decreases platelet aggregation and decreases CD40 ligand release [120]
Statins Improves endothelial function [121]
Dexmethasone Decrease inflammation [122]
Nix-0699 Uncertain, but inhibits acute painful crisis [44, 123, 124]
Intravenous immunoglobulin (IVIG) Decreases the number of leukocytes & acute pain episodes [44, 123, 124]
Vorinostat, panobinostat HDAC inhibition [113]
GMI-1070 Pan-selectin inhibitor [45]
Propranolol Inhibits RBC adhesion to the endothelium [125]
Regadenoson A2AR agonist, blocks iNKT activation [126]
Zileuton 5-lipoxygenase inhibitor, used in asthma [127]
Fructose-1,6-diphosphate (FDP) Reduces ischemia–induced tissue damage [128]
Prasugrel ADP receptor blockade [129]
MP4CO PEG carboxy-hemoglobin [130]
Acetyl-L-carnitine Decreases lipid peroxidation [90]
Alpha-lipoic acid Inhibits NFkB, increases glutathione [131]
NAC Increased glutathione [132]
Omega-3 fatty acids Decreases VOC events [18]
Glutamine Increases NADPH [133]
IV magnesium Vasodilatation [134]
Aes-103 Binds sickle hemoglobin and shifts oxy-hemoglobin dissociation curve to the left [90]
Poloxamer-188 Non-ionic surfactant, improves micro-vascular flow [135]
L-arginine Substrate for NO [116]
HbF fetal hemoglobin, NO nitric oxide, RBC red blood cell, IVIG intravenous immunoglobulin, HDAC Histone deacetylases, Nix-0699 Niprisan, GMI-1070 Rivipansel,
FDP Fructose-1,6-diphosphate, NADPH Nicotinamide adenine dinucleotide phosphate, A2AR Adenosine A2A receptor, PEG Polyethylene glycol, ADP Adenosine
diphosphate, iNKT Invariant natural killer T cells
Few drug candidates may exhibit multiple mechanisms of action
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in these patients. Arginine supplementation through ex-
ogenous sources can restore low GAB. Arginine supple-
mentation is quite successful in treating patients with
leg ulcers, pulmonary hypertension and pain. Arginine
supplementation along with hydroxyurea increases level
of HbF and nitrite [29]. Preliminarily outcome of phase
2 clinical trial showed that reduced arginine induces
pain and vaso-occlusive crisis (VOC) which is alleviated
through arginine supplementation in SCD patients [30].
L-arginine is converted to citrulline and nitric oxide
(NO) by the enzyme NO synthase (NOS). Beneficial ef-
fect of NO has been observed in SCD patients having
acute chest syndrome, hypoxia and pulmonary hyperten-
sion [31]. NO is pivotal in the expression of sickle cell
VOC as it plays an important role in both vascular vaso-
dilatation allowing blood to flow easily, and in reducing
the adhesiveness of sickled erythrocytes to the vascular
wall. It also reduces platelet aggregation and protects the
blood vessels from free radicals [32]. Low level of L-
arginine is observed in HbSS adults, which decreases
further during severe pain episodes [33, 34]. Over ex-
pression of NO synthase under reduces arginine concen-
tration, thereby producing ROS, increasing the oxidative
stress and reducing NO availability in these patients
[35]. Inhaled NO was found to reduce the time period
and episode of an acute VOC in children affected with
this disease. Sildenafil, which is an oral phosphodiester-
ase -5 inhibitor, is known to amplify the production of
endogenous NO which in turn causes an increase in
HbF production [36].
Role of micronutrients
There is ample evidence linking lower levels of zinc with
increased painful crisis in SCD patients. The increased
daily zinc requirement in SCD patients, which is not
met by the usual intake, is a consequence of hyper zin-
curia caused by increased hemolysis [37, 38].
Also alterations of several parameters of cellular im-
mune functions in SCD patients have been related to a
deficiency of zinc [37]. Zinc supplementation to pre pu-
bertal aged sickle cell anemia patients was found to be
beneficial on their linear growth and weight [39]. Zinc
sulphate has been found quite effective in reducing
RBC’s dehydration. It was also found to reduce sickle
cell crises, pain and other life-threatening complications.
Zinc supplementation not only improved growth and
weight of SCD children, but also gave a boost to their
immunity by offering antibacterial protection, thereby
making its supplementation essential. Besides zinc, mag-
nesium was found to protect against losses of water and
potassium in SCD patients [39, 40]. Magnesium defi-
ciency was found to increase episodes of sickling by
causing cell dehydration in sickled erythrocytes [40]. In
SCD patients It has been found that magnesium supple-
mentation reduced the number of dense erythrocytes
and also improved the erythrocyte membrane transport
abnormalities of patients with SCD [41].
Copper deficiency is linked to anemia, being a key in-
gredient for functioning of metalloenzymes (e.g. cerulo-
plasmin), and plays an important role in iron
metabolism. Ceruloplasmin helps to mobilize stored iron
in the liver and make it more available for synthesis of
Hb. Importantly, in copper deficiency anemia the syn-
thesis rate of Hb is reduced, despite increased iron levels
in the liver [42, 43].
Chromium is another element which helps in the
management of SCD. It acts not only as a cofactor, at
receptor sites of the insulin sensitive cell membrane
but it also plays a role in carbohydrate metabolism
which is the body’s much required energy source in
SCD.
Manganese (Mn) which helps in glycoprotein synthesis
and bone formation is also important for management
of SCD. It also acts as cofactor of pyruvate carboxylase
which participates in the respiratory chain reaction
Fig. 1 Nutrient deficiencies contributing to the vicious cycle in sickle cell disease
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required for the much needed energy production, for
SCD patients [44, 45].
Role of vitamins
As compared to their peers, SCD children are known to
show decreased height and weight resulting in poor
growth. Blood deficiency of several vitamins such as A,
B6, C, D,& E and minerals like zinc, Mg is observed in
patients with SCD by many researchers, which are the
most factors contributing towards their poor growth and
weight [46, 47]. These deficiencies cause a significant re-
duction in the concentrations of blood antioxidant levels
in SCD patients resulting in VOC related ACS [48]. Re-
searches supplementing vitamins E and C and minerals,
magnesium and zinc either alone or in combination
proved beneficial outcome in reducing the sickling pain
crisis [49]. The decrease in concentration of antioxidant
vitamins A, C, and E is responsible for increased
hemolysis and susceptibility to bacterial infections in
SCD. Decreases in arterial blood pressure reduction in
the percentage of sickle cells, was observed with a col-
lective supplementation of vitamins like A, C, and E, be-
sides an increase in concentration of hemoglobin and
packed cell volume [50, 51]. In vitro studies also estab-
lished that vitamin E possesses anti-sickling property
and therapeutic benefits in sickle cell anemia cases [52].
As nutritional deficiency plays a significant role in SCD
complication, educating the patients on specific nutrient
and calorie needs should be emphasized. Proper care
must be provided about their dietary intake, ways of pro-
viding nutritious meals (particularly among the low in-
come group), and means for enhancing protein and
calorie consumption [46].
Administration of 1 mg vitamin B12 intramuscularly
for a period of around 3 months showed significant
symptomatic improvement in SCD patients. This study
also confirmed that in cases of severity, these patients
may undergo unrecognized deficiency of vitamin B12
[53]. Most of the pediatric patients display an adequate
status of vitamins B6 and B12, but raised levels of
plasma homocysteine along with a low folate levels. Fol-
ate supplementation would be beneficial to these pa-
tients, as it lessens their risk for endothelial damage
[20]. Vitamin B6 is known for its crucial roles in differ-
ent metabolic pathways in the body like ingestionof food,
derivatization to the fueling molecule glucose and assist-
ing in the metabolism of lipids and proteins. The bio-
logical potent form of vitamin B6, namely pyridoxal 5’
phosphate (PLP) functions as a cofactor for many of the
enzymes involved in amino acid metabolism as well as
the formation of neurotransmitters like serotonin, dopa-
mine, epinephrine, and gamma amino-butyric acid.
SCD patients are prone to bone fractures and often
the vitamin D status is found to be very low, putting
them at great risk. Routine supplementation with vita-
min D helps maintain the vitamin levels in such
patients [54].
Proposed mechanisms for developing nutrient
deficiencies in SCD
Proposed mechanisms of under nutrition may include
dysfunctions in protein metabolism, cytokine related ap-
petite suppression, enhanced cardiac energy output, and
increases in erythrocyte levels [55, 56].
Hyper metabolism characterized by increased catabol-
ism and lowered anabolism increases the calorific de-
mand in SCD patients [57]. This is represented as
increased resting energy expenditure (REE). A shortened
lifespan of sickle cell blood cells causes an increased en-
ergy demand of the body. Hence their requirement of
energy to sustain the normal functions of growth,
physiological functioning and physical activity are not
met. Increased energy requirements that are not
followed by a concomitant calorific intake render an
impaired growth status in these patients. Some re-
searchers propose that frequent bouts of illnesses and
hospitalization might have adverse effects on the fre-
quency of food intakes and energy [55]. Also erythropoi-
esis increases the resting energy required in SCD.
Researchers suggest that enhanced production of eryth-
rocytes, increased cardiac output, and increased turn-
over of protein is possibly responsible for increased REE
and protein requirements in SCD [58].
As SCD patients have lowered RBC concentration
and are anemic, an elevation in resting cardiac indices
is observed. In order to maintain and supply oxygen to
the different tissues of the body, workload on the car-
diac system is increased, thereby triggering a state of
chronic inflammation. A study estimated the average
hemoglobin synthesis to be ~ 0.725 g/kg/d in HbSS
adults as compared to just 0.094 g/kg/d in their
healthy counterparts. This results in an enhanced cell
turnover in the bone marrow, and an increased glu-
tamine uptake, thus leading to a depletion of the
body’s glutamine levels. Further the study showed that
pre-pubertal SCD children utilize 19 % more calories,
about 58 % of more protein, and 47 % greater amount
of glutamine than healthy children of their ages [59].
Large energy deficits due to a higher basal metabolic
rate are regarded as one of the possible factors contrib-
uting towards poor growth in SCD individuals. This
relatively low energy intake in younger children is also
contributory to growth abnormalities [60]. Associations
of protein intake and other macronutrients with growth
measurements are limited due to studies that are not
well structured and also smaller sample sizes. Protein
utilization too appears compromised because of certain
amino acid deficiencies. Hence the presence of orotic
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acid is observed in normal subjects with low intakes of
protein which is similar to that observed in SCD
patients [60].
Dysfunctional signaling of the hypothalamus and the
inflammatory cytokines induced reduction in neuropep-
tide Y (NYP) release; appear to be responsible in causing
changes in energy provided to the body. Inflammation
may promote energy expenditure in a regulatory feed-
back manner to fight against energy supply in the per-
ipheral organs/tissues as well as in the central nervous
system. Blockage of the N YP leading to the suppression
of appetite has been associated with noticeable weight
loss and lowered physical activity. Other factors contrib-
uting to a reduced food intake may be also due to pain,
fear, and other psychological stressors [61]).
Role of interleukins
Higher levels of IL-1 and IL-6 have been linked with in-
creased morbidity risk in SCD [62]. Patients with en-
hanced IL-6, C-reactive protein, IL-1β, and TNF-α
exhibit threshold changes in their sense of taste,and odor
thereby affecting their dietary intakes [63]. Animal ex-
periments associate IL-1 concentrations with food in-
takes and satiety by triggering the neurons in the
hypothalamus. Hence antagonist IL-1beta receptors have
been found to be alleviated in anorexia [64].
Leptin is another pro inflammatory cytokine known to
regulate the feeding behavior, and energy utilization [65].
The cytokine IL-6 known to modulate the levels of lep-
tin has also been implicated in anorexia though another
study shows contrary results. Weight loss has been
shown to result in a lowered production of leptin which
is proportional to the loss of body fat [66].
Dysfunctional eating patterns
Psychological and social stresses, not to mention the ex-
treme pain and the restricted activity, drive the SCD
child to dysfunctional eating. Difficulty in eating and eat-
ing things not considered as food which are characteris-
tic symptoms of pica, lead to nutritional deficiencies
which go unnoticed by the clinician. Although one
fourth of SCD children are affected by pica, it has not
gained the focus of health care providers. Searching for
biological explanations makes the clinician focus on as-
pects unrelated to psychological stressors [67].
Dehydration
One of the important factors affecting cell sickling is the
loss of water in the cell. The migration of potassium and
chloride ions carrying water across the RBCs causes de-
hydration, which consequently increases the tendency of
the hemoglobin to polymerize and sickle. Studies show a
potential therapeutic solution to reduce the cell sickling
by blocking the loss of electrolytes from erythrocytes
through two ion transport pathways, namely the K-Cl
co -transporter and the Ca2 + -activated K+ channel [68].
Possible role of lipids
The role of dietary lipids deserves specific mention be-
cause, phospholipids composition of the membrane
lipids in sickle cell erythrocytes show distinct abnormal-
ities which may have a direct bearing upon the dehydra-
tion and abnormal sodium and potassium metabolism
known to occur in sickle erythrocytes. This also has a
direct impact on cellular function [69]. The increased
permeability of sodium and potassium in the deoxygen-
ated sickle cell leads to an overload on the renal system
causing its damage [70]. In combination with the protein
abnormality of hemoglobin, these molecular changes in
membrane phospholipids composition may accentuate
the sickling phenomena and perhaps, impart to the crisis
in these patients.
Potential nutritional approaches for SCD
Benefits from nutritional supplements in the manage-
ment of SCD and its associated clinical conditions have
strengthened considerations of nutritional aspects apart
from the genetic one. Possible approaches for nutritional
intervention to attain optimal immune and nutritional
status for prevention of the related disease symptoms
and reduction of morbidity and mortality in SCD pa-
tients are being explored. Use of dietary supplements to
patients irrespective of age has shown improvements in
growth and protection against infections [71].
Traditional herbal therapy
Many herbs that contain beneficial phyto compounds
have been used since ancient times to reduce sickling as
well as the painful episodes. Leaf extracts of Carica pa-
paya and Parquetina nigrescens, root extracts of Fagara
zanthoxyloides, and seed extracts of Cajanuscajan, con-
tain phyto-antioxidants, which may act either alone or
synergistically to augment the anti-sickling activity of
these plants.(67) The Congolese plant Justicia secunda
containing anthocyanins was found to exhibit potential
antisickling effects [72, 73]. Eugenia caryophyllata and
Piper guineense contain vanilloids like Shikimic acid and
cannaboids that are of benefit in reducing the painful
episodes by mechanisms similar to that of the opiates
[74], F.zanthoxyloides, natively called fagara has been
used for the reduction of painful episodes in SCD. Nico-
san is a popular and safe Nigerian anti sickling herbal
remedy inhibiting hemoglobin S polymerization [68].
Bioassay experiments show that maximum reduction in
sickling was observed by the leaf extracts of C. papaya at
concentrations of 5 mg/mL [52] probably due to
relatively high total phenol content exhibiting high free
radical scavenging activity. Though many of these phyto-
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medicines have proved beneficial, further multicentric
researches are required to validate their usage.
Antioxidant therapy
SCD is one of the many diseases in which oxidative
stress plays a significant role affecting the RBCs, and
leading to inflammation and the resulting pain. Levels of
antioxidants seem to be compromised in SCD [75]. Dur-
ing management of clinical cases, the exacerbated iron
load due to hemolysis and multiple transfusions potenti-
ates ROS generation. Among several antioxidants
known, the phenolic compounds isolated from plants,
namely the flavonoids are very important. Supplementa-
tion of natural antioxidants vitamins such as A, C, and E
have been shown to decrease the number of irreversibly
sickled cells, the arterial blood pressure, and concentra-
tion of mean corpuscular Hb concentration with con-
comitant increases in packed cell volume (PCV}
concentration [52].
The cyclic cascade leading to complications of cell ad-
hesion and VOC, triggers production of ROS further in-
tensifying the disease symptoms. As oxidative stress
plays a pivotal role in SCD patients during VOC, the use
of antioxidants to improve the clinical status seems es-
sential. In-vivo studies on antioxidants using animal
models have shown promising results. Ascorbic acid has
shown effectivity as a potent antioxidant at as low as 0.1
millimolar concentrations [76]. A 10 week supplementa-
tion of vitamin E showed a decrease in the cell sickling
from 25 % to 11 % [77].
However, clinical studies using vitamin E have shown
poor success rates and found no significant differences
in cell adhesion and lipid peroxidation levels [78]. This
has prompted Ohnishi etal to advocate a mixture of an-
tioxidants in the suppression of SCD symptoms [20]. It
has been suggested that the generation of free radicals in
SCD may overpower the strength of exogenous antioxi-
dants and therefore a mixture of antioxidants may prove
beneficial. Also the generation of ROS due to external
factors of diet, environment, and co-morbidities associ-
ated with SCD, needs to be well explored and evaluated.
Well defined studies showing effects of the two different
types of antioxidants on severity of symptoms in SCD
should be performed. Antioxidants providing enzyme
defense (such as SOD, catalase, GPX, and hemo- oxy-
genase -1) and antioxidants scavenging different free
radicals (such as vitamins E,C, GSH) should be inde-
pendently considered [79]. Also in spite of enhanced
levels of antioxidant intake in SCD is being advocated so
far, no established standardization exists. Therefore it
becomes difficult to generalize the results of a particular
study for antioxidant usage or future therapy [80]. Fu-
ture research should target specific ROS generation de-
pots using different antioxidant combinations to reduce
SCD complications. However, limited phase three clin-
ical trials are available due to the complex pathophysi-
ology in SCD [77].
Use of dietary lipids and omega- 3 fatty acids
The popular lipid food additive butyric acid has been
found to increase levels of HbF in the blood and
stabilize the mental mood. Experimental evidence sug-
gests that the two short chain fatty acid derivatives
namely α methyl hydrocinnamic acid and 2, 2 dimethyl
butyrate offer significant therapeutic benefits as they
induce fetal γ globin expression in SCD. They are fur-
ther found to stimulate HbF cells with erythroid prolif-
eration at quite low doses than the existing phenyl
butyrate and butyrate [81].
A striking enhancement in the concentration of lipid
constituents in sickle cells is observed when matched
with similarly aged erythrocytes. Also the erythrocytes
left unsickled, occupy a larger surface area, appearing
flattened as compared to normally aged cells [82]. Ab-
normalities in the membrane lipid composition in SCD
appear to have a direct impact on the cellular functions.
Phospholipid composition of the membrane in sickle cell
erythrocytes shows distinct abnormalities [46]. Deficien-
cies of certain polyunsaturated fatty acids and their sub-
sequent replacement by monounsaturated and saturated
fatty acids may be related to dehydration and the un-
characteristic sodium and potassium transport in sickled
erythrocytes. This could not only help in possible cor-
rections through exogenous supplementation of these
fatty acids, but also serve as a useful diagnostic marker
[46]. Pilot studies suggested that supplements containing
omega-3 fatty acids may decrease the painful hemolytic
and VOC and improve the membrane fatty acid com-
position [18]. The omega-3 fatty acids namely eicosa-
pentaenoic acid (EPA), and docosahexaenoic acid(DHA),
are two important structural and functional constituents
of the RBCs which have been shown to inhibit haemoly-
sis and vasoocclusion, thereby reducing the number of
VOC in SCD [18, 83, 84]. In addition, omega-3 fatty
acids diminish the expression of intercellular adhesion
molecule-1, leukocyte adhesion to vascular endothelium,
and the production of four biologically active molecules
involved in the pathophysiology of tissue damage in
SCD,namely the interleukins (IL)-1β, IL-6, and IL- 8 and
tumor necrosis factor-alpha [85]. Furthermore, it has
been observed that the greater the quantity of EPA and
DHA in the blood, the lower the risk of developing com-
plications of SCD and the lesser the degree of anemia
[86, 87]. Their affordability over other current therapies
in non-affluent countries where the overwhelming ma-
jority of people affected by sickle cell disease live makes
it a feasible option. The diverse anti-aggregatory, anti-
adhesive, and anti-inflammatory role of omega-3 fatty
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acids makes it a promising therapeutic candidate for the
prevention of cell sickling and reduction of the painful
crisis in SCD [18].
Use of amino-acids
Antisickling action of many plants of medicinal value
and other naturally existing compounds may be attrib-
uted to the presence of amino acids [88]. Phenylalanine
present in an herbal plant Cajanuscajan, and hydroxy-
benzoic acid present in another medicinal plant of the
Vitex family are thought to be the reason for their anti-
sickling effect [89]. Amino acids display their antisickling
behavior by increasing the cell volume of the RBC’s,
thereby decreasing the concentration of intracellular
hemoglobin below the gelling threshold [90]. The possible
mechanism of action leading to the antisickling effect by
phenylalanine, is reported to involve the liposomal trans-
port system, as well as the Na+/K+ transport system [91].
The aromatic compound L-phenylalanine benzyl ester
acts as an antisickling agent, and is found to possess
potential therapeutic properties beneficial in the treat-
ment of SCD [92].
Use of opioids
Individuals addicted with opiates often experience severe
macro and micro nutrient deficiencies which renders
their protein and carbohydrate metabolism inefficient.
Being indifferent to the basic necessities of life makes
them impoverished and undernourished. This makes
them underweight with a lowered immunity, hormonal
imbalances, prone to infections and organ damage. Al-
terations in the levels of certain specific nutrients may
also hinder their addiction withdrawal. Moreover lack of
nutritional education leads them to unhealthy eating be-
haviors. Unfortunately addiction centers do not identify
nutritional programs as a major influencing factor. Ef-
fective supplementation of large amounts of protein and
amino acids during de addiction, may be required to
boost their nutritional status [93].
Opoids exhibit their beneficial anti analgesic activity
by either exerting their histaminergic effect, excitatory
effect, dopaminergic effect or proserotonergic effect [94].
A fear of addiction to narcotics by patients, giving rise
to ethical issues [95] has also led to its controlled usage.
Use of intranasal fentanyl in a pediatric emergency set-
ting was related with a considerably reduced time to at-
tain analgesia as compared with morphine, administered
parenterally, and caused minimum distress to children
[96] Experiences from managing pain in children could
well be then extrapolated to adults.
Current new approaches
In response to anemia, the kidneys secrete erythropoi-
etin which is the major non-immunological cytokine
that regulates erythropoiesis. Therefore serum levels of
erythropoietin are often increased in SCD wherein
chronic anemia is observed [94]. Erythropoietin’s ability
to provide a stimulus in HbF production could be used
for clinical trials. This raise in HbF gives us a lead that
human erythropoietin could be used favorably in SCD as
it either increases availability of oxygen and nutrients or
produces proteins favoring growth and healing. This is
also observed in supplementation with HU [53].
The anti-fungal compound clotrimazole, appears to
block the Ca2 + -activated K+ channels in RBCs and in
smooth muscle cells via the cytochrome P450 [97]. Re-
searches are on to experiment this compound in con-
junction with other bioactive compounds for long term
treatment.
Ozone being the allotrope of oxygen, possesses healing
properties which are yet to be completely understood.
Bocci et al. observed that ozone activates a number of
biochemical pathways, which are very useful in vascu-
lopathies, particularly chronic limb ischemia [98]. The
rationale for using ozone therapy in SCD appears to be
based upon its action on the endothelium thereby en-
hancing the release of NO and prostacyclin and sup-
pressing the release of endothelin-1(a vaso constriction
affecting peptide that is increased during cell injury and
insult) [99]. Careful blood ozonization appears to be one
of the few effective procedures for correcting chronic
oxidative stress [99].
Significant progress has been achieved in gene therapy
approaches for treatment of SCD [100]. Gene therapy in
SCD patients has been known to target major repressor
proteins implicated during development [10]. Gene ther-
apy approaches in SCD mice decreased anemia and
hyper leukocytosis, reduced the accumulation of iron in
liver, and enhanced splenic and renal function. Thus,
modest chimerism with the donor cells exhibiting high
levels of HbF from a γ-globin lentiviral vector that is in-
sulated can mend the pathological status in SCD mice.
This would render a safer and effective option of gene
therapeutics in humans [101]. Talano et al. have shown
the usage of alternative allogeneic donors which can ei-
ther be familial haploidentical (FHI) donors, matched
unrelated donors (MUD), or unrelated cord blood do-
nors (UCB). These therapies have ensued in high sur-
vival rate among SCD patients. Now due to these
advanced approaches, a lot of people having chronic
SCD conditions are able to receive curative allogenic
stem cell therapies [16].
Newer non-invasive therapies like lung extension to ease
the airway pressure, pulse oximetry, and incentive spirom-
etry hold potential for future treatments [102]. Continuous
positive airway pressure (CPAP) therapy treated subjects
exhibited lesser pain, improved cognition, and a decreased
apnea-hypopnea index. The intensity of pain days was
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reduced from 2.3 days to 0.8 days per week for each patient
[103]. A dysfunction in the hemoglobin of SCD and a right-
shifted oxyhemoglobin dissociation curve (ODC) alter the
oxyhemoglobin saturation (SpO2) values that can be mea-
sured by pulse oximetry which is a non-invasive method
[104]. Incentive spirometry [105],as well as positive expira-
tory pressure therapies also showed a great promise espe-
cially in children who may experience hypoventilation
when administered high doses of opiates for painful VOC
crisis [106].
Conclusion
SCD is well known to be an inherited disorder with a
disruptive metabolic status causing immense pain and a
compromised life for the patient. Different patterns of
culture, unmet economic needs, lack of health education
and nutritional awareness place the sickle cell disease
patient to increased risk of dietary deficiencies leading to
pain and problems. These nutritional deficiencies may
surface either due to lowered intake of specific nutrients
or malfunctioning in the metabolic pathway or alter-
ations at the genetic level.
Though HU therapy is clinically very promising, cer-
tain areas like lowering of sperm counts in males [107],
instability in the genetic makeup through deregulation
of telomere repeat binding factor 2 (TRF2) and telomere
dysfunction [108] is a matter of concern. This calls for
further researches for compounds to alleviate the pain
and improve the condition of patients with SCD. Nutri-
ents with their immense benefits could add to the pre-
vention and curative aspects of SCD. Also translation of
genetic technology,particularly epigenetic nutrition could
well pave the way to better SCD patient care [109].
Though much has been reported about nutritional
supplements and their benefits, little has changed in
clinical practice. Also larger well-structured multi-
centric studies need to be addressed to arrive at conclu-
sive evidence-based recommendations by a scientific
body. This would then gain the much required attention
on nutritional aspects by clinicians, and benefit the SCD
patient.
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